3AC Stock Overview
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Actinogen Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.02 |
| 52 Week High | AU$0.029 |
| 52 Week Low | AU$0.0075 |
| Beta | 2.27 |
| 1 Month Change | 21.21% |
| 3 Month Change | 21.21% |
| 1 Year Change | -18.37% |
| 3 Year Change | -29.82% |
| 5 Year Change | 900.00% |
| Change since IPO | -65.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3AC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.1% | 2.2% | -1.0% |
| 1Y | -18.4% | -22.2% | 2.2% |
Return vs Industry: 3AC exceeded the German Biotechs industry which returned -22.2% over the past year.
Return vs Market: 3AC underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 3AC volatility | |
|---|---|
| 3AC Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 3AC's share price has been volatile over the past 3 months.
Volatility Over Time: 3AC's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Steve Gourlay | www.actinogen.com.au |
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer’s disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Actinogen Medical Limited Fundamentals Summary
| 3AC fundamental statistics | |
|---|---|
| Market cap | €44.35m |
| Earnings (TTM) | -€9.14m |
| Revenue (TTM) | €2.95m |
15.1x
P/S Ratio-4.9x
P/E RatioIs 3AC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3AC income statement (TTM) | |
|---|---|
| Revenue | AU$4.79m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$4.79m |
| Other Expenses | AU$19.66m |
| Earnings | -AU$14.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0064 |
| Gross Margin | 100.00% |
| Net Profit Margin | -310.26% |
| Debt/Equity Ratio | 0% |
How did 3AC perform over the long term?
See historical performance and comparison